Welcome to our dedicated page for Niagen Bioscience news (Ticker: NAGE), a resource for investors and traders seeking the latest updates and insights on Niagen Bioscience stock.
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging, and its news flow reflects that specialization. Company announcements frequently highlight developments around its patented nicotinamide riboside ingredient Niagen®, the Tru Niagen® consumer supplement line, and the Niagen Plus™ intravenous and injectable platform.
Readers following NAGE news can expect updates on product launches and line extensions, such as Tru Niagen Beauty, which combines Niagen with clinically studied ingredients to support the appearance of hair, skin, and nails. News items also cover commercial partnerships and distribution milestones, including the expansion of pharmaceutical-grade Niagen Plus IV and injections into hundreds of clinics and wellness centers across the United States.
Because Niagen Bioscience emphasizes evidence-based positioning, a significant portion of its news relates to clinical and scientific progress. This includes publication of randomized controlled trials using Niagen in specific populations, summaries of peer-reviewed research on NAD+ biology, and the evolution of educational platforms like AboutNAD®, which curates NAD+ research for consumers, clinicians, and scientists.
Investors and observers will also find regular coverage of financial and corporate developments, such as quarterly earnings releases, changes to full-year outlook, share repurchase authorizations, and intellectual property transactions involving core nicotinamide riboside patents. For anyone tracking the NAD+ category, the NAGE news page offers an ongoing view into how Niagen Bioscience advances its science, expands its product ecosystem, and manages its capital and IP strategy. Bookmark this page to monitor new studies, product initiatives, and regulatory or market updates that the company discloses over time.
Niagen Bioscience (NASDAQ: NAGE) has confirmed that its operations remain unaffected by recent global tariffs, primarily due to its U.S.-based manufacturing strategy. The company's flagship product Niagen® (patented nicotinamide riboside) is manufactured, encapsulated, and bottled domestically by partner W.R. Grace.
The company's strategic decision to maintain a U.S.-based supply chain has proven beneficial, with only a minimal portion of materials sourced internationally. Additionally, nicotinamide riboside (NR) currently maintains an exempt status from recent tariffs, allowing uninterrupted international operations.
In 2024, 24% of the company's revenue came from international sales, with 12% specifically from A.S. Watson in Hong Kong, a duty-free market unaffected by tariffs. The company expects to maintain current costs, pricing, and product delivery capabilities.
Niagen Bioscience (NASDAQ: NAGE) has secured U.S. Patent 12,252,506 for nicotinamide riboside (NR) salt forms, strengthening its NAD+ precursor intellectual property portfolio. The composition of matter patent, exclusively licensed from Queen's University Belfast, covers various NR salt forms including NR Malate and NR Tartrate, as well as other derivatives.
The patent grants Niagen exclusive rights for different NR salt forms and manufacturing methods until 2034. The company's IP portfolio now includes over 90 patents related to its flagship Niagen® ingredient, positioning it as a leader in NAD+ precursor development. According to CEO Rob Fried, any company developing products using these NR salt forms would infringe on this patent.
The protected salt forms include carboxylic acid, dicarboxylic acid, aminodicarboxylic acid, phosphate, sulfate, carbonate, and carbamate salts for nutritional supplement use. Niagen Bioscience claims to be the only company capable of producing NR and its salt forms at commercial scale without patent violation.
Niagen Bioscience, Inc. (Nasdaq: NAGE), formerly ChromaDex Corp., announced its corporate rebranding and new ticker symbol effective March 19, 2025. The company, a global authority on NAD+ with over 25 years of legacy, focuses on healthy aging through its flagship product Niagen, a patented nicotinamide riboside (NR) ingredient.
The company reported strong financial performance with full-year 2024 net sales of $99.6 million, up 19% year-over-year, and maintains $44.7 million in cash with no debt. Their product portfolio includes Tru Niagen, the #1 NAD+ boosting oral supplement in the US, and Niagen Plus, a pharmaceutical-grade IV and injectable version available by prescription at 475 clinics nationwide.
The rebranding reflects the company's evolution and success in NAD+ research, supported by over 35 human clinical studies on Niagen. The executive team will commemorate this milestone at the Nasdaq Closing Bell Ceremony on March 19, 2025.